Erythromycin
As of the edition of 20 October 2026, Erythromycin is a small molecule: marketed, first approved in 1956 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Erythrocin
- First approved
- 1 February 1956 (ES)
- Approvals on record
- 26 in 5 regions
- Holder of the most recent approval
- Biofrontera; 15 holders in all
- Registered trials
- 53, 4 stopped early
- Disease areas
- Lungs and airways; Digestive system; Urinary and reproductive; Inherited and neonatal; Immune system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 16 | 7 | 1 | 3 |
| Phase 1 | 17 | 17 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 1 |
| Phase 3 | 6 | 4 | 0 | 0 |
| Phase 4 | 10 | 6 | 2 | 0 |
| All trials | 53 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Almirall | Applicant | 1984 to now |
| Healthpoint | Later holder | 1985 to now |
| Johnson & Johnson | Acquired holder, Later holder and Lead sponsor of trials | 1985 to now |
| Paddock | Later holder | 1986 to now |
| AbbVie | Later holder | 1987 to now |
| Eli Lilly | Acquired holder | 2003 to now |
| Pfizer | Acquired holder and Lead sponsor of trials | 2005 to now |
| Viatris | Acquired holder | 2017 to now |
| Bausch Health | Acquired holder | 2019 to now |
| Azurity Pharmaceuticals | Acquired holder | 2022 to now |
| Dr. Reddy's | Acquired holder | 2023 to now |
| Abbott | Earlier holder | |
| Westwood Squibb Pharmaceuticals | Later holder |